CAMBRIDGE, Mass.–(BUSINESS WIRE)–Korro Bio, Inc., a biotechnology company developing single-base RNA editing therapies, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present an update on Korro’s progress at the 39th Annual J.P. Morgan Healthcare Conference.
The presentation will take place on Thursday, January 14, 2021 at 8:05 a.m. E.T. using a virtual platform.
About Korro Bio, Inc.
Korro is leading the next frontier in RNA therapeutics. Its proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), harnesses the body’s own RNA editing system to make a precise edit to a single-base. Korro’s therapeutic approach utilizes synthetic oligonucleotides to repair disease-causing mutations at the RNA level. This approach can also be used to create therapeutically beneficial versions of proteins to improve patient outcomes. (Read more…) Korro’s programs target a broad portfolio of innovative RNA editing therapies in the liver, eye and central nervous system. The company was founded in 2018 by Atlas Venture and is funded by Atlas Venture, New Enterprise Associates, Wu Capital, Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Cormorant Asset Management, MP Healthcare Venture Management and Alexandria Venture Investments. For more information, visit korrobio.com.
Contacts
Mary Carmichael
Ten Bridge Communications
mary@tenbridgecommunications.com